Tralokinumab, topical corticosteroids combination beneficial in Atopic dermatitis

Published On 2021-11-09 12:11 GMT | Update On 2021-11-09 12:11 GMT

Atopic dermatitis (AD), is a common chronic or recurrent inflammatory skin disease and affects 15-20% of children and 1-3% of adults worldwide. Cyclosporine A (CSA) is a popularly used in AD, but treatment with CSA has potentially serious adverse effects. A phase 3 trial Capsinoids plus topical corticosteroids (TCS) as needed provided early and sustained improvements in AD signs and symptoms.

A randomized trial by J. Gutermuth and team revealed that tralokinumab 300 mg plus topical corticosteroids as needed was effective and well tolerated in patients with severe AD not adequately controlled with oral corticosteroids or who had contraindications to them.

For more details, check out the full story on link below:

Tralokinumab Plus Topical Corticosteroids Effective In Severe Atopic Dermatitis

Full View

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Tralokinumab, topical corticosteroids combination beneficial in Atopic dermatitis

Similar News